Lode J Swinnen
Overview
Explore the profile of Lode J Swinnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
2669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tabbara N, Zahurak M, Zahurak M, Sterling C, Sterling C, Trutzer I, et al.
Blood Adv
. 2024 Dec;
9(5):1202-1209.
PMID: 39693511
Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow...
2.
Batchelor T, Giri S, Ruppert A, Geyer S, Smith S, Mohile N, et al.
Blood Adv
. 2024 Apr;
8(12):3189-3199.
PMID: 38598710
Although it is evident that standard-dose whole-brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We...
3.
Kahl B, Jegede O, Peterson C, Swinnen L, Habermann T, Schuster S, et al.
J Clin Oncol
. 2024 Jan;
42(7):774-778.
PMID: 38194625
JCO In 2003, the Eastern Cooperative Oncology Group initiated a randomized phase III clinical trial (E4402) comparing two different rituximab dosing strategies for patients with previously untreated low-tumor burden follicular...
4.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, et al.
J Natl Compr Canc Netw
. 2023 Nov;
21(11):1118-1131.
PMID: 37935098
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the...
5.
DeZern A, Zahurak M, Symons H, Cooke K, Huff C, Jain T, et al.
Blood
. 2023 Apr;
141(25):3031-3038.
PMID: 37084383
Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality. It is treated with bone marrow transplantation (BMT) for those with fully matched donors, or immunosuppressive...
6.
Horbinski C, Nabors L, Portnow J, Baehring J, Bhatia A, Bloch O, et al.
J Natl Compr Canc Netw
. 2023 Jan;
21(1):12-20.
PMID: 36634606
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2-3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO...
7.
Sterling C, Hughes M, Tsai H, Yarkony K, Fuchs E, Swinnen L, et al.
Transplant Cell Ther
. 2022 Dec;
29(4):267.e1-267.e5.
PMID: 36549386
The use of post-transplantation cyclophosphamide (PTCy) for graft-versus host-disease (GVHD) prophylaxis has revolutionized allogeneic blood or marrow transplantation (alloBMT), but there is limited published experience in peripheral T cell lymphoma...
8.
Hughes M, Sterling C, Varadhan R, Ambinder R, Jones R, Sweren R, et al.
Leuk Lymphoma
. 2022 Aug;
63(12):2987-2991.
PMID: 35915978
No abstract available.
9.
Zelenetz A, Gordon L, Chang J, Christian B, Abramson J, Advani R, et al.
J Natl Compr Canc Netw
. 2021 Nov;
19(11):1218-1230.
PMID: 34781267
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of...
10.
Rappazzo K, Zahurak M, Bettinotti M, Ali S, Ambinder A, Bolanos-Meade J, et al.
Transplant Cell Ther
. 2021 Aug;
27(11):909.e1-909.e6.
PMID: 34425261
High-dose post-transplantation cyclophosphamide (PTCy) is an effective platform for prevention of severe graft-versus-host disease (GVHD) after allogeneic bone marrow (BM) transplantation with mismatched unrelated donors (mMUDs). Previous studies evaluating PTCy...